Seock-ah A. Im

Seoul, Republic of Korea

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 569 publications

Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial.

Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial.

Journal: The Lancet. Oncology
Published: April 24, 2026

New perspectives on endocrine therapy suitability for hormone receptor-positive metastatic breast cancer in clinical practice.

New perspectives on endocrine therapy suitability for hormone receptor-positive metastatic breast cancer in clinical practice.

Journal: Breast (Edinburgh, Scotland)
Published: April 08, 2026

Clonal Hematopoiesis and Risk of Trastuzumab-Related Cardiotoxic Effects.

Clonal Hematopoiesis and Risk of Trastuzumab-Related Cardiotoxic Effects.

Journal: JAMA oncology
Published: April 02, 2026

Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2- -associated high-risk HER2-negative early breast cancer: Updated results from the OlympiA phase III trial.

Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2- -associated high-risk HER2-negative early breast cancer: Updated results from the OlympiA phase III trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: February 25, 2026

A randomized phase III trial of anthracyclines followed by taxane versus taxane plus carboplatin as (neo)adjuvant therapy in patients with triple-negative breast cancer: KCSG BR 15-1 PEARLY trial.

A randomized phase III trial of anthracyclines followed by taxane versus taxane plus carboplatin as (neo)adjuvant therapy in patients with triple-negative breast cancer: KCSG BR 15-1 PEARLY trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: February 08, 2026

Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer.

Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer.

Journal: The New England journal of medicine
Published: January 21, 2026

Outcomes in KEYNOTE-355 after chemotherapy discontinuation before pembrolizumab discontinuation and with immune-mediated adverse events.

Outcomes in KEYNOTE-355 after chemotherapy discontinuation before pembrolizumab discontinuation and with immune-mediated adverse events.

Journal: NPJ breast cancer
Published: December 15, 2025

Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer.

Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer.

Journal: The New England journal of medicine
Published: December 10, 2025

The clinical value of clinical treatment score post-5 years in patients with premenopausal breast cancer: a retrospective analysis of ASTRRA trial.

The clinical value of clinical treatment score post-5 years in patients with premenopausal breast cancer: a retrospective analysis of ASTRRA trial.

Journal: Breast (Edinburgh, Scotland)
Published: December 10, 2025

Durvalumab plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer.

Durvalumab plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 26, 2025

Clinical and Molecular Evaluation of HER2-Low and HER2-Ultralow Breast Cancer in the Penelope-B Clinical Trial Cohort.

Clinical and Molecular Evaluation of HER2-Low and HER2-Ultralow Breast Cancer in the Penelope-B Clinical Trial Cohort.

Journal: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
Published: November 05, 2025

Comprehensive analysis of FGFR2b and its correlation with essential biomarkers, intratumoral heterogeneity, and survival in advanced gastric cancer.

Comprehensive analysis of FGFR2b and its correlation with essential biomarkers, intratumoral heterogeneity, and survival in advanced gastric cancer.

Journal: British journal of cancer
Published: November 03, 2025
Showing 1-12 of 569

Last Updated: 09/26/2026